The late 1980s and the 1990s were something of a gold rush for pharmaceutical companies focused on CNS drug development — especially those developing psychiatric drugs. In 1988, Eli Lilly introduced the blockbuster SSRI Prozac (fluoxetine), then a new type of antidepressant. Big Pharma companies launched several SSRIs in the years that followed. By the…
CenExel Clinical Research Acquires Apex Innovative Sciences
Clinical research firm CenExel has announced that it will acquire Apex Innovative Sciences, which is the parent of Collaborative Neuroscience Research (CNS) and Hassman Research Institute (HRI). The Salt Lake City–based company will rename the latter two organizations CenExel CNS and CenExel HRI, respectively. CenExel CNS and CenExel HRI operate five clinical research sites based…
Unlock advanced CBD formulations with nutritional lipids
Cannabidiol (CBD) is fast emerging as an exciting ingredient across the pharmaceutical market, powered by increasing scientific research investigating its potential benefits in a number of disease states, including central nervous system (CNS) disorders, pain management, cancer and more. While there is a remarkable opportunity for the development of CBD-based solutions in the field, formulation…